PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 21, 2026The Journal of Prevention of Alzheimer s Disease1 citationsOpen Access

Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data

View Full Paper
BSB. SchelterUniversity of AberdeenHSHelen ShiellsUniversity of AberdeenSLSerena LoUniversity of Aberdeen

Key Points

  • Evaluate the efficacy of hydromethylthionine mesylate in treating tau pathology associated with mild cognitive impairment and Alzheimer's disease.
  • Compared HMTM treatment with existing control data from CPAD and ADNI.
  • Utilized meta-analytic controls for broader analysis of treatment efficacy.
  • Evidence suggests HMTM treatment offers significant clinical benefits.
  • Treatment was found to be accessible with low burden for both patients and physicians.

Abstract

Comparisons of HMTM treatment with CPAD, ADNI, and meta-analytic controls provide evidence consistent with clinical benefit HMTM. It has the potential to offer an accessible oral treatment option which could be delivered with minimal patient/physician burden.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schelter et al. (2026) studied this question.

synapsesocial.com/papers/69e7132bcb99343efc98cf4bhttps://doi.org/10.1016/j.tjpad.2026.100560
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease2026 · 7 citations
  2. 2Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer's disease explains unexpected phase 3 trial results2026 · 1 citations
  3. 3The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease2011 · 10,376 citations
  4. 4Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine2008 · 105 citations
  5. 5Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data2020 · 15 citations